Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Other Non-Current Assets data on record, last reported at $29.9 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 26.21% year-over-year to $29.9 million; the TTM value through Sep 2025 reached $29.9 million, up 26.21%, while the annual FY2024 figure was $26.0 million, 0.32% changed from the prior year.
  • Other Non-Current Assets reached $29.9 million in Q3 2025 per AMPH's latest filing, up from $28.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $29.9 million in Q3 2025 and bottomed at $7.2 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $20.5 million, with a median of $20.9 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 286.7% in 2021, then dropped 6.47% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $16.7 million in 2021, then rose by 25.15% to $20.9 million in 2022, then rose by 24.23% to $25.9 million in 2023, then grew by 0.32% to $26.0 million in 2024, then grew by 14.9% to $29.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $29.9 million in Q3 2025, $28.1 million in Q2 2025, and $23.0 million in Q1 2025.